Introduction {#Sec1}
============

The overall incidence of long bone fractures in the Western world is estimated to be between 300 and 400 individuals per 100,000 per year \[[@CR1], [@CR2]\]. The majority of trauma-induced fractures in adults will heal within nine months \[[@CR3]\]. For progressive union of a fracture, the factors combined in the so-called diamond concept need to be present: an adequate cellular environment, sufficient growth factors, a bone matrix and mechanical stability. Apparently 5--30% of the patients lack one of these factors, because they will develop complications during the healing process, leading to delayed union or even non-union of the fracture \[[@CR4]\]. These complications may induce prolonged hospitalisation and secondary interventions with concomitant inconveniences and costs. Especially for those patients, but eventually for all patients with fractures, treatments that positively influence bone healing and subsequently shorten the time necessary for bone union are of great interest.

Healing of fractures and time to union can be improved by biophysical stimulation or by administration of biological substances, such as autologous bone grafts or platelet-rich plasma (PRP). The optimal administration dose and the identity of the active substances in these preparations are largely unknown. Recent studies into the mechanism of fracture repair have resulted in the identification of more specific compounds for intervention. Examples are the parathyroid hormone (PTH), hypoxia-inducible factor 1α (HIF-1α), modulators of the Wnt signalling pathway and the bone morphogenetic proteins (BMPs) \[[@CR5]\]. The administration of defined compounds instead of heterogeneous mixtures of proteins may result in better treatment options and could also offer financial advantages. Promising candidates are the BMPs, which were originally identified as the active components in bone extracts capable of inducing de novo bone formation at ectopic sites \[[@CR6], [@CR7]\]. This review will focus on the application of recombinant human BMPs (rhBMPs) in bone repair.

BMPs {#Sec2}
====

Eventhough earlier observations had been made, Urist published in 1965 the conclusive observations on the induction of cartilage and bone by demineralised segments of bone \[[@CR6]\]. The osteoinductive activity was found to be induced by a family of proteins present in bone, which were named BMPs \[[@CR8]\].

BMPs are a subfamily of the transforming growth factor-β (TGF-β) superfamily, also comprising activins and inhibins. Thus far, around 20 different proteins have been named BMP in humans, but not all members are truly osteogenic (Table [1](#Tab1){ref-type="table"}). The bone-inducing BMPs can be divided into several subgroups, according to homology of their amino acid sequences \[[@CR9], [@CR10]\]. BMP-2 and BMP-4 comprise one subgroup; the second group consists of BMP-5, BMP-6, BMP-7 and BMP-8, while BMP-9 and BMP-10 form the third osteogenic group \[[@CR9], [@CR11]\]. The other members of the BMP family do not posses osteogenic properties. BMP-1 is actually a metalloprotease and not a member of the superfamily \[[@CR12]\], whereas BMP-3 and BMP-13 function as BMP antagonists/inhibitors rather than as BMPs \[[@CR13], [@CR14]\]. Table 1Overview of BMP characteristicsSubfamilyBMPSynonymsInvolved inRefs.1BMP-2BMP-2ABone and cartilage formation\[[@CR7], [@CR76]\]BMP-4BMP-2BTeeth and bone formation\[[@CR76]--[@CR78]\]2BMP-5Cartilage development\[[@CR79]\]BMP-6Vgr-1Joints, liver\[[@CR80], [@CR81]\]BMP-7OP-1Renal development, kidney\[[@CR82], [@CR83]\]BMP-8OP-2Bone and cartilage formation\[[@CR84]\]BMP-8B3BMP-9GDF-2CNS, liver, angiogenesis\[[@CR78], [@CR85]--[@CR87]\]BMP-10Morphogenesis of the heart\[[@CR78], [@CR88]\]OthersBMP-1Metalloprotease, cartilage development\[[@CR12]\]BMP-3OsteogeninBMP inhibitor, bone formation\[[@CR13]\]BMP-3BGDF-10\[[@CR20]\]BMP-13GDF-6, CDMP-2BMP inhibitor, tendons\[[@CR14]\]BMP-11GDF-11CNS\[[@CR78]\]BMP-12GDF-7, CDMP-3Tendons, cartilage\[[@CR89]\]BMP-14Cartilage\[[@CR78], [@CR90]\]BMP-15GDF-9Oocyte development\[[@CR91]\]BMP-16?\[[@CR92]\]*GDF* growth differentiation factor, *CDMP* cartilage-derived morphogenetic protein

In bone, BMPs are produced by osteoprogenitor cells, osteoblasts, chondrocytes and platelets \[[@CR15], [@CR16]\]. After their release, the extracellular matrix functions as a temporary storage for BMPs. The regulatory effects of BMPs depend upon the target cell type, its differentiation stage, the local concentration of BMPs, as well as the interactions with other secreted proteins \[[@CR4]\]. BMPs induce a sequential cascade of events leading to chondrogenesis, osteogenesis, angiogenesis and controlled synthesis of extracellular matrix \[[@CR10]\] (see Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Schematic overview of BMP expression during different stages of fracture healing \[[@CR74], [@CR75]\]. The indicated days are dependent on the bone and fracture type

The BMPs exert their effects through binding as dimers to type I and type II serine/threonine kinase receptors, forming an oligomeric complex (Fig. [2](#Fig2){ref-type="fig"}). The type II receptors are constitutively active and phosphorylated and consequently activate the type I receptors upon oligomerisation. Subsequently, the activated type I receptors phosphorylate intracellular effector proteins, the receptor-regulated Smads (R-Smads), Smad1, Smad5 and Smad8. Upon activation, the Smads associate with the Co-Smad, Smad4, and translocate into the nucleus, where they associate with other transcription factors and bind promoters of target genes to control their expression \[[@CR10], [@CR17]--[@CR20]\] (Fig. [1](#Fig1){ref-type="fig"}). Fig. 2Regulation of the BMP signalling pathway during bone formation. *1* BMP binds to BMP receptor type II (BMP-RII). *2* BMP/BMP-RII complexes with BMP receptor type I (BMP-RI), which is then phosphorylated. *3* BMP-RI phosphorylates the regulatory Smad1, Smad5 and Smad9, after which a complex is formed with Smad4. The complex is transported to the nucleus and the regulation of target genes occurs, leading to bone formation. Further regulation of the signalling pathway takes place at various levels. *4* Extracellular BMP inhibitors, e.g. chordin, noggin, Tsg, gremlin, follistatin and BMPER. *5* Receptor antagonists, e.g. BMP-3, BMP-13. *6* Membrane pseudo-receptors, e.g. BAMBI, CRIM1, and co-receptors, e.g. endoglin. *7* Intracellular inhibitors, e.g. Smad6, Smad7, Smad8b, Smurf1, Smurf2

BMP antagonists and modulators {#Sec3}
==============================

The activity of BMPs is locally regulated by a number of antagonists. High expression of BMP antagonists will negatively influence fracture healing. These antagonists can be subdivided into molecules that act extracellularly or intracellularly. Extracellular antagonists such as noggin, chordin, twisted gastrulation (Tsg), gremlin, follistatin and BMPER are cystine knot-containing proteins forming complexes with BMPs, thereby preventing them to bind their receptors \[[@CR18], [@CR19], [@CR21]--[@CR24]\]. Another secreted antagonist is BMP-3, which induces activation of a TGF-β/activin-like pathway and as a consequence inhibits signalling by osteogenic BMPs and bone formation \[[@CR18], [@CR21], [@CR25]\]. Inhibition of BMPs can also occur at the cell membrane. CRIM1, a transmembrane protein, with cysteine-rich repeats similar to chordin, regulates the rate of processing and delivery of BMPs to the cell surface \[[@CR26]\]. The pseudo-receptor BAMBI (BMP and activin membrane-bound inhibitor) is a transmembrane protein of which the extracellular domain shares high sequence similarity with type I receptors, but which lacks the intracellular kinase domain and is thought to inhibit BMP signalling by interfering with receptor complex formation \[[@CR27]\]. Endoglin (CD105) is a transmembrane co-receptor involved in the regulation of a number of members of the TGF-β superfamily, including TGF-β and BMPs. Down-regulation of endoglin results in decreased signalling of BMPs, demonstrating a positive regulatory effect on BMP activity \[[@CR28], [@CR29]\]. Intracellular antagonists such as Smad6, Smad7 and Smad8b and Smurf1 and Smurf2 intervene with the activation of R-Smads and/or facilitate their proteasomal degradation (Fig. [2](#Fig2){ref-type="fig"}). Furthermore, apart from its C-terminal phosphorylation by BMP type I receptors, Smad1 can be phosphorylated by the Erk, P38 and JNK MAP kinases and subsequently by GSK-3, which results in cytoplasmic retention and increased proteasomal degradation of Smad1 \[[@CR30], [@CR31]\].

In conclusion, the mere presence of BMPs is no guarantee of efficient bone healing. Although the presence of BMPs is essential for a number of processes during bone healing, BMP-mediated bone formation strongly depends on the local presence of various BMP activity regulating inhibitors and stimulators.

Treatment with BMPs {#Sec4}
===================

Clinical use of BMPs {#Sec5}
--------------------

Based on various animal studies and preclinical trials, several clinical studies have been performed to demonstrate the efficacy of BMPs in accelerating bone regeneration and fracture healing \[[@CR32]--[@CR35]\]. The osteogenic potency of the BMPs requires a local and controlled delivery. Moreover, for clinical use of BMPs, their short half-life time should be taken into account. Several delivery systems have been developed to overcome this limitation \[[@CR4], [@CR36]--[@CR38]\].

For clinical use [rhBMP-2]{.ul} (dibotermin alfa), with the product names InductOs® (UK) and InFUSE (US), is supplied within a bovine collagen sponge carrier, allowing slow release over time. This combination has been thoroughly investigated and was approved by the US Food and Drug Administration (FDA) in 2004 \[[@CR39]\]. Govender et al. evaluated the effects of rhBMP-2 treatment in 450 patients with open tibial fracture in a prospective setup \[[@CR32]\]. Implantation of rhBMP-2 in a collagen sponge led to a significantly higher union rate, reduced time to union, improved wound healing, reduced infection rate and fewer secondary invasive interventions in the group treated with rhBMP-2.

The other clinically used BMP, [rhBMP-7]{.ul}, with the brand names Osigraft® (UK) and OP-1 Putty (US), is supplied in 1 g bovine collagen carrier in granular form \[[@CR40]\]. In small but randomised trials, the positive effect of rhBMP-7 on repair of scaphoid non-unions and fibular defects was demonstrated \[[@CR41], [@CR42]\]. Administration of rhBMP-7 showed better formation of bone and bridging of the segmental defects compared to controls. Giannoudis and Tzioupis evaluated the type of indications and the efficacy for treatment with rhBMP-7 \[[@CR34]\]. A variety of clinical conditions, such as persistent fracture non-unions, augmentation of periprosthetic fracture treatment and osteotomies, enhancement of fracture healing following acetabular reconstruction, distraction osteogenesis, free fibular graft and arthrodesis of joints, were treated with rhBMP-7. Of 653 cases, the overall success rate was 82% (535 cases) \[[@CR34]\]. Ristiniemi et al. treated 20 patients with distal tibial fractures that had been stabilised with external fixation with rhBMP-7 in bovine collagen \[[@CR43]\]. Healing of the fracture was compared with that of 20 matched patients who received the same treatment only without BMP-7. In the patients treated with rhBMP-7, significantly more fractures had healed and time to union was shorter. They concluded that BMP-7 enhanced the union of distal tibial fracture.

The potency of rhBMP-2 and rhBMP-7 has recently been compared, in vitro and in vivo \[[@CR44]\]. In vitro, both agents increased the alkaline phosphatase (ALP) production, which indicated osteogenic differentiation, but the production of ALP was markedly higher in the rhBMP-2 group than in the rhBMP-7 group. However, in vivo rhBMP-7 produced significantly larger ossicles, with significantly more bone and mineral content. Other in vivo studies showed that rhBMP-2 could be more potent than rhBMP-7 \[[@CR23]\]. These contradictory results could be the effect of the different working mechanisms and of the different time frames of the single BMPs during the process (see Fig. [1](#Fig1){ref-type="fig"}) and therefore also depend on the scaffold in which the BMPs are administrated \[[@CR10]\]. These problems could be circumvented by using more sophisticated scaffolds, which could even allow the use of both BMPs in an optimised time frame, with early release of BMP-2 followed by BMP-7 in a later stage \[[@CR37]\].

Platelets contain considerable amounts of BMPs and the treatment of fractures with PRP is at least in part based on BMPs \[[@CR15]\]. Calori et al. showed, however, that the application of rhBMP-7 as a bone-stimulating agent is superior compared to that of PRP with regard to their clinical and radiological efficacy \[[@CR33]\].

Although various animal and preclinical studies have demonstrated the powerful osteoinductive properties of single recombinant human BMPs, the results of clinical trials with rhBMP-2 and rhBMP-7 are less impressive. This was also concluded in a recent Cochrane review, in which similar times for fracture healing between controls groups and groups treated with BMP-2 or BMP-7 were demonstrated \[[@CR45]\]. Several possible explanations have been suggested, such as rapid tissue clearance and lack of responding cells at time of administration \[[@CR46]\]. Some of the (endogenous) factors possibly contributing to the limited efficacy of BMP administration will be discussed in the "[Blocking antagonists](#Sec8){ref-type="sec"}" section.

Adverse effects of BMPs {#Sec6}
-----------------------

Several side effects have been suggested for the use of rhBMPs in fracture healing. Especially with regard to the supra-physiological doses, ectopic bone formation and stimulation of cancer cells are being studied. Recombinant BMP-2 has recently been shown not to be associated with pancreatic cancer in a study with more than 90,000 patients \[[@CR47]\]. The most frequently described adverse effect is the development of antibodies against the administrated rhBMPs or against the bovine collagen carrier \[[@CR32], [@CR38]\]. This immunogenic reaction was found to be positively correlated with higher doses of BMP and collagen. No correlation between the immune response to bovine collagen and treatment failure was demonstrated, and no clinical manifestations of an immune response or allergies to bovine collagen were found. Side effects of BMP-2 such as ectopic bone formation in fracture treatment and critical soft tissue swelling for cervical spine fusions have also been observed. However, these were associated with the use of very high BMP doses in animal studies, varied among species, and ultimately remodelling to the normal bone contour occurred. Nonetheless, BMPs remain a potent treatment option to enhance fracture healing with low risk of adverse events if correctly used. After administration of rhBMPs, biological negative feedback loops are activated resulting in the production of BMP antagonists and culminating in diminished rhBMP activity, probably influencing therapeutic efficacy. The historical approach of administrating larger amounts of BMPs in an effort to enhance the efficacy might result in the opposite effect. Recent studies using sophisticated biomaterials as BMP carriers show better results with lower doses, corresponding more with physiological concentrations \[[@CR48]\].

Cost-effectiveness of rhBMPs {#Sec7}
----------------------------

Next to the side effects, the use and costs of rhBMPs are also under debate. BMPs are delicate to handle, expensive to manufacture and supra-physiological doses are used, resulting in high costs. Nevertheless several studies indicate that despite these costs the clinical use of BMP-2 and BMP-7 is still recommended from a health economic point of view \[[@CR49], [@CR50]\]. Cost reductions for hospitals are mainly related to shorter surgery time due to the absence of the bone grafting procedure and faster discharge of the patient. For the patients treated with rhBMP-2, the time to return to work is significantly reduced, as is the risk of revision surgery \[[@CR49]\]. In a comparative study BMP-7 treatment was found to be as efficient as autologous bone graft, but the average cost was 6.78% higher, mainly due to the price of BMP-7 \[[@CR50]\]. A systematic review on the clinical and cost-effectiveness of BMPs concluded that the use of BMPs was associated with a reduced operating time, improvement in clinical outcomes and a shorter hospital stay as compared to the use of autograft \[[@CR51]\]. The proportion of secondary interventions tended to be lower in the BMP group than in the controls, but this was not statistically significant. In non-unions, there is no evidence that BMP treatment is more or less effective than bone grafts; however, it is currently used when bone grafts and other treatments have failed. According to the results of economic evaluation, for spinal fusion the use of BMP is unlikely to be cost-effective \[[@CR51]\]. As for any novel treatment, further studies, preferably randomised, controlled blinded and with sufficient power and proper controls, are needed to assess the clinical effectiveness of the use of BMPs for bone union \[[@CR52]--[@CR54]\]. These studies are currently being performed, e.g. BMP-7 for tibial fractures in Ghent, Belgium (NCT00551941). The issue of cost-effectiveness should be discussed afterwards.

One important issue, the expensive manufacturing of BMPs, can be overcome by new and cheaper production methods, such as the method described by von Einem et al. for rhBMP-2 \[[@CR55]\]. Another alternative could be the use of inexpensive compounds that locally stimulate the induction of BMPs. Statins have been shown to increase the expression of BMP-2 \[[@CR56]\]. Locally applied simvastatin improved fracture healing in a rat model similar to the effect of BMP-2 \[[@CR57]\]. Statins are relatively cheap and well-tested drugs and their BMP-stimulating properties may contain new possibilities in terms of fracture healing. In this respect, the recently discovered soluble form of the BMP activity-enhancing co-receptor endoglin also deserves future investigation \[[@CR28]\].

Blocking antagonists {#Sec8}
====================

Because rhBMP treatment has some disadvantages, the quest for alternative treatment is still ongoing. Blocking of the function of BMP antagonists may provide such an alternative. By inhibiting BMP antagonists an environment can be created in which the rhBMP therapy will be more effective. The best effects will be reached by inhibition of factors antagonising BMP activity at the level of the callus \[[@CR23]\]. To date, very little literature is available about the manipulation of BMP antagonists to promote bone healing in humans. The BMP inhibitor α2-HS-glycoprotein (Ahsg) was found to control the osteogenic potency of ectopically applied BMP \[[@CR58]\]. The BMP antagonist noggin showed potential clinical applications in a mouse model \[[@CR25]\]. Noggin-suppressed osteoblasts are suggested as a method of treatment to avoid the need for exogenous application of BMPs \[[@CR59]\]. The use of inhibiting monoclonal antibodies against sclerostin, an indirect BMP antagonist \[[@CR60]\], has shown increased bone formation in rodents and primates, suggesting a therapeutic role in osteoporosis \[[@CR24]\]. By manipulating the balance with antagonists, endogenous BMP activity can be up-regulated throughout the process of fracture healing, avoiding issues of timing, dose and delivery. These preliminary findings suggest that antagonists may have a therapeutic role in regulating the size or shape of BMP-containing implants and in preventing heterotopic ossification.

Application of other BMP family members {#Sec9}
=======================================

Several studies investigating the potential of BMPs indicated that other members of the BMP family, different than the currently used BMP-2 and BMP-7, might provide attractive alternatives for fracture treatment (Table [2](#Tab2){ref-type="table"}). In vitro, most human BMPs were able to stimulate osteogenesis in mature osteoblasts, but BMP-6 and BMP-9 were more efficient in driving osteoblast differentiation of mesenchymal stem cells than BMP-2 and BMP-7 \[[@CR17]\]. BMP-6 and BMP-9 were also found to be more effective osteogenic factors in a mouse model for bone regeneration compared to BMP-2 and BMP-7 \[[@CR61]\]. Moreover, BMP-6, BMP-9 and BMP-4 showed more osteogenic potential than the approved rhBMPs in a rat model \[[@CR9]\]. Also in rat, an adenoviral vector carrying BMP-6 (AdBMP-6) produced more rapid tissue calcification and induced bone formation by both intramembranous and endochondral ossification compared to an adenoviral vector containing BMP-2 (AdBMP-2) or BMP-4 (AdBMP-4) \[[@CR62]\]. Although these model studies suggest an effect of BMP-4 and BMP-6 on fracture healing, the osteogenic activity of these BMPs has not yet adequately been investigated in humans (Table [1](#Tab1){ref-type="table"}). Recently, BMP-6 displayed significantly more pronounced BMP reporter activation, osteoblast differentiation and stimulation of fracture healing than the most closely related family member BMP-7 \[[@CR19], [@CR63]\]. The higher ultimate effect is not due to the stimulating potential of BMP-6, but due to differences in the noggin-mediated negative feedback loop induced by these BMPs. Upon siRNA-mediated knockdown of noggin, BMP-7 appeared to be as effective in inducing BMP reporter activation and osteoblast differentiation as BMP-6. BMP-6 stimulation not only resulted in lower induction of noggin expression compared to BMP-7, but BMP-6 was also found to be almost insensitive to noggin-mediated inhibition. A lysine at position 60 (Lys-60) was identified as a key residue conferring noggin resistance within the BMP-6 protein, and introducing a lysine residue at the position corresponding to BMP-6 Lys-60 in BMP-7 and BMP-2 made these mutants more resistant to inhibition by noggin. Interestingly, BMP-9 also contains a lysine residue at this position and is, like BMP-6, not inhibited by noggin \[[@CR18], [@CR19]\]. BMP-9 also emerged as one of the most potent inducers of osteogenic differentiation \[[@CR9], [@CR17], [@CR36], [@CR61], [@CR64], [@CR65]\]. BMP-9 was shown to promote chondrogenic lineage differentiation of human multipotent mesenchymal cells. BMP-9 was more potent to maintain the expression of chondrocyte-specific extracellular matrix molecules than BMP-2 \[[@CR66]\]. Combined injection in mice of BMP-9 and BMP-3, a known inhibitor of BMPs, resulted in the formation of bone, indicating that BMP-3 did not have the inhibiting effect which it has on other BMPs \[[@CR61]\]. The highly increased osteogenic activity observed with BMP-9 may be due to the fact that it is not affected by BMP antagonists such as noggin and BMP-3, essentially removing the negative feedback loop. Alternatively, it is possible to engineer BMP variants, such as variants of the currently used BMP-2 and BMP-7, with increased noggin resistance by substituting the amino acid residue corresponding to BMP-6 Lys-60 for a lysine residue. An alternative for the current treatment with BMP-2 or BMP-7 homodimers, the use of BMP-2/7 heterodimers could also be considered. These heterodimers display increased osteogenic potential and improved fusion compared with BMP homodimers \[[@CR67]\]. Interestingly, BMP-2/7 heterodimers were found to induce lower levels of noggin expression and to be almost insensitive to noggin inhibition \[[@CR68]\]. Recently, heterodimers of BMP-2/6 have been shown to bind more strongly to BMP receptors and are more osteogenic than BMP-2 \[[@CR69]\]. Table 2Properties of several BMPs. The resistance to noggin is caused by a lysine residue at position 60 in the molecule. Also the ability to induce differentiation in pluripotent and preosteoblastic cells is described. The possible induction of mineralised matrix by the different BMPs is described. The potency of superior BMPs with reference to less potent BMPs is explained BMP-2BMP-6BMP-7BMP-9Resistance to nogginNo \[[@CR18], [@CR19]\]Yes \[[@CR19]\]No \[[@CR19]\]Yes \[[@CR18], [@CR19]\]Inducing differentiation in stem cells \[[@CR17]\]Notable increase in inductionNotable increase in inductionDetectable, but marginal inductionNotable increase in inductionInducing differentiation in preosteoblastic cells \[[@CR17]\]Marked increase in inductionMarked increase in inductionIncrease of induction at later time pointMarked increase in inductionInduction of mineralised matrix \[[@CR17]\]Readily detectable nodulesReadily detectable nodulesSparse, but detectable nodulesReadily detectable nodulesSpecific BMP more potent than other BMPs More potent than BMP-2 \[[@CR62]\] Higher induction of expression with specific molecules than BMP-2 \[[@CR66]\]

Finally, another approach to enhance BMP-induced bone formation might be a combination with TGF-β. TGF-β is generally considered to inhibit BMP signalling \[[@CR70], [@CR71]\]. However, recently we demonstrated that the inhibitory effects of TGF-β on BMP-induced osteoblast differentiation depend on the timing and environmental conditions of the co-stimulation, and that under well-controlled conditions, transient co-application of TGF-β can actually promote BMP-induced differentiation towards the osteoblast lineage \[[@CR72]\]. Co-application of TGF-β1 with BMP-2 has been shown to accelerate bone formation, to increase total bone volume and to improve fracture healing in mice compared to application of BMP-2 alone \[[@CR73]\]. Since TGF-β seems to stimulate early BMP-induced osteoblast differentiation whereas it inhibits late osteoblast differentiation and mineralisation, it can be considered to initially combine BMP and TGF-β treatment followed by application of TGF-β antagonists to enhance the bone fracture healing process.

Conclusion {#Sec10}
==========

The efficacy of the use of BMPs to enhance fracture healing is still controversial. The BMPs currently used to enhance bone fracture healing, rhBMP-2 and rhBMP-7, are expensive and have side effects. Other BMPs, such as BMP-6 and BMP-9, were shown to be more potent in vivo and might turn out to be more effective for the treatment of delayed and non-union fractures. As a consequence of the resistance of BMP-6 and BMP-9 to noggin-mediated inhibition, lower, more physiological amounts of these BMPs will be needed to improve fracture healing. Optimisation of the BMP products used and cheaper production methods will inevitably stimulate the clinical use of BMPs for bone fracture healing. A lot of questions still have to be solved to establish when and where the use of BMPs is the most profitable and effective.
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